- Home
- AXS vs RGEN Comparison
AXS vs RGEN Comparison
Compare AXS & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXS
- RGEN
- Stock Information
- Founded
- AXS 2001
- RGEN 1981
- Country
- AXS Bermuda
- RGEN United States
- Employees
- AXS N/A
- RGEN N/A
- Industry
- AXS Property-Casualty Insurers
- RGEN Medical/Dental Instruments
- Sector
- AXS Finance
- RGEN Health Care
- Exchange
- AXS Nasdaq
- RGEN Nasdaq
- Market Cap
- AXS 8.1B
- RGEN 8.0B
- IPO Year
- AXS N/A
- RGEN N/A
- Fundamental
- Price
- AXS $98.64
- RGEN $128.04
- Analyst Decision
- AXS Strong Buy
- RGEN Buy
- Analyst Count
- AXS 9
- RGEN 12
- Target Price
- AXS $107.75
- RGEN $172.67
- AVG Volume (30 Days)
- AXS 565.0K
- RGEN 830.2K
- Earning Date
- AXS 04-30-2025
- RGEN 04-29-2025
- Dividend Yield
- AXS 1.78%
- RGEN N/A
- EPS Growth
- AXS 54.31
- RGEN N/A
- EPS
- AXS 10.08
- RGEN N/A
- Revenue
- AXS $6,055,200,000.00
- RGEN $650,429,000.00
- Revenue This Year
- AXS $4.15
- RGEN $13.93
- Revenue Next Year
- AXS $5.74
- RGEN $14.35
- P/E Ratio
- AXS $9.84
- RGEN N/A
- Revenue Growth
- AXS 5.79
- RGEN 4.88
- 52 Week Low
- AXS $68.02
- RGEN $102.97
- 52 Week High
- AXS $101.42
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- AXS 54.06
- RGEN 44.98
- Support Level
- AXS $99.27
- RGEN $123.10
- Resistance Level
- AXS $102.36
- RGEN $135.47
- Average True Range (ATR)
- AXS 2.21
- RGEN 6.85
- MACD
- AXS 0.17
- RGEN -0.74
- Stochastic Oscillator
- AXS 59.21
- RGEN 19.54
About AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.